Rituxan fails Phase III lupus trial
This article was originally published in Scrip
Executive Summary
Genentech and Biogen Idec have terminated development of their blockbuster monoclonal antibody Rituxan (rituximab) for the treatment of lupus nephritis after it failed to reduce disease activity in a Phase III trial, LUNAR, investigating it in combination with mycophenolate mofetil (MMF) and corticosteroids.